Researchers have identified glutathione peroxidase 4 (GPX4) as a therapeutic target in abdominal aortic aneurysm, a vascular disease characterized by permanent and focal dilatation of the abdominal aorta, with a mortality rate of up to 85% in case of rupture.
A recent study by researchers from Texas A&M University presented a new vaccine designed to target the ligand-binding domain of the serotonin 2A receptor (5-HT2AR), which resides in the second extracellular loop (EL2) and was previously identified as the key region for receptor activation. The new candidate, called EL2-5HTVac, was shown to provide a long-lasting and selective therapeutic approach to avoid increased bleeding risk complications.
Rona Therapeutics Co. Ltd. has obtained IND clearance from China′s National Medical Products Administration (NMPA) for RN-1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) for hypertension.
Bristol Myers Squibb Co. has identified serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular, cerebrovascular, metabolic, inflammatory, neurological and immunological disorders, among others.
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2046 for heart failure after acute myocardial infarction.
FK506-binding protein-like (FKBPL) is an immunophilin protein family member with critical functions in physiological and pathological angiogenesis. Its therapeutic peptide derivative AD-01, currently a preclinical peptide candidate, targets angiogenesis via CD44. AD-01 acts both as a vascular stabilizer and an anti-inflammatory agent under pro-inflammatory conditions.
Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has entered into a development and license agreement with Yuva Biosciences Inc. to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions using Yuva’s mitochondrial science-focused platform Mitonova, powered by AI.
Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and functional abnormalities.
Regenerative heart therapy, integrating biocompatible materials with nucleic acids, proteins and live cells, offers a promising personalized approach to treating cardiac ischemic reperfusion injury and heart failure.
RSS
